Prosecution Insights
Last updated: November 19, 2026
Application No. 17/793,635

METHOD AND KIT FOR DNA ISOLATION

Non-Final OA §103§112
Filed
Jul 18, 2022
Priority
Jan 24, 2020 — GB 2001034.4 +1 more
Examiner
HIBSHMAN, SARAH GRACE
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Global Life Sciences Solutions Germany GmbH
OA Round
3 (Non-Final)
40%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
23 granted / 57 resolved
-19.6% vs TC avg
Strong +45% interview lift
Without
With
+44.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
23 currently pending
Career history
89
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
39.7%
-0.3% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
25.6%
-14.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Office Action

§103 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04/24/2026 has been entered. Status of the Application Receipt is acknowledged of Applicants’ amendment and remarks, filed on 04/24/2026, in which claims 1, 3, 7-8, 13, 17, 22, and 26 are amended, and claims 2, 10, 25, and 27 are canceled. Claims 1, 3-9, 11-24, and 26 are pending and are examined on the merits herein. Priority The instant application is a 371 of PCT/EP2021/051046 filed on 01/19/2021, which claims foreign priority to UK 2001034.4, filed on 01/24/2020. Objections and Rejections Withdrawn Applicant’s amendment and remarks, filed 04/24/2026 regarding the objections to the specification in that the terms Nonidet, Igepal, Triton, and Tween should be accompanied by generic terminology has been fully considered and is persuasive, as the proposed substitute specification submitted 04/24/2026 provides generic terminology Applicant’s amendment and remarks, filed 04/24/2026, with respect that claims 8, 17, 22, and 26-27 are rejected under 35 U.S.C. 112(b) as containing the trade name Triton has been fully considered and is persuasive, as claims 8, 17, and 26 are amended to remove the trade name Triton, and claim 27 is canceled. This rejection has been withdrawn. Applicant’s amendment and remarks, filed 04/24/2026, with respect that claims 2 and 27 are rejected under 35 U.S.C. 103 as being unpatentable over Welker has been fully considered and is persuasive, as claims 2 and 27 are canceled. This rejection has been withdrawn. The following are modified grounds of objection and rejection. Objection to the Specification The use of the term Tris, which is a trade name or mark used in commerce, has been noted in this application. For example, in the instant specification the term Tris appears at least on page 14 line 4. The terms should be accompanied by the generic terminology. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. Response to Arguments Applicant's arguments filed 04/24/2026 have been fully considered but they are not persuasive. Applicant states that the term "tris", which appears in "tris-HCl" is not a trade name (page 7, paragraph 3). This is not persuasive. A trademark has been granted for TRIS, as indicated by tmsearch.uspto.gov/search/search-results/73772479. Trademarks/trade names may not be included in claims. The examiner suggests that the specification be amended to include an indication that, in generic terminology, Tris is 2-Amino-2-(hydroxymethyl)propane-1,3-diol. Because it is known in the art that Tris-HCl corresponds to the IUPAC name 2-Amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride, as demonstrated by PubChem CID 6503 (PTO-892), this would not constitute addition of new matter. The objection is maintained. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 18-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 18-19 contain the trademark/trade name Tris. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe a surfactant and, accordingly, the identification/description is indefinite. Response to Arguments Applicant's arguments filed 04/24/2026 have been fully considered but they are not persuasive. Applicant states that the term "tris", which appears in "tris-HCl" is not a trade name (page 7, paragraph 3). This is not persuasive. A trademark has been granted for TRIS, as indicated by tmsearch.uspto.gov/search/search-results/73772479. Trademarks/trade names may not be included in claims. The examiner suggests the use of the IUPAC name 2-Amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride. Because it is known in the art that Tris-HCL is 2-Amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride, this would not constitute addition of new matter. Because Applicant’s arguments are not persuasive, the instant claims are rejected for the reasons of record with modifications made to account for the claim amendments filed 04/24/2026. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 4-7, 11, 13, 16, 19-24, and 26 are rejected under 35 U.S.C. 103 as being unpatentable over Welker et al. (WO 2018/140452; IDS 07/18/2022). Welker discloses methods for enriching cell-free DNA (cfDNA) fragments from a biological fluid sample (abstract). Analysis of cfDNA is used in genetic testing for genetic disorders and has applications in prenatal screenings and the detection of certain genes that are associated with cancer [003]. Welker teaches that the biological fluid sample is a bodily fluid including, among others, blood plasma, serum, or urine [0039]. Welker describes collection of a blood sample, stating that, for example, a blood sample can be taken from one of the superficial veins of a human subject's upper limb [0052]. The sample can be collected by any conventional means [0052]. Welker further teaches that biological samples can also include extracts from a biological sample, such as for example an extract from a biological fluid (e.g., blood or urine) [0038]. Welker discloses methods for isolating large cfDNA and for isolating small cfDNA. A description for the enrichment of small cfDNA from a biological sample begins at [0077], and is outlined in Figure 3, which is reproduced below. PNG media_image1.png 925 350 media_image1.png Greyscale In this method for the enrichment of small cfDNA, serial additions of an alcoholic solution – a first low alcohol solution followed by a second, high alcohol solution – are used to enrich a biological fluid sample with small cfDNA fragments [0077]. Welker teaches that the first reaction solution formed by combining the biological sample eluate, the alcoholic solution, the chaotropic agent, DNA-binding particles, and any other components has an alcohol concentration of 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21 %, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, or 10% v/v alcohol [0077]. Welker, in Example 3 beginning at [00126], discloses a method for enrichment of small cfDNA of 20-60 bp. In this example, 4 volumes of binding solution was added to 1 volume of pretreated sample. The binding solution comprises 2.5 M guanidine thiocyanate, 10% Triton, 40% isopropanol, and magnetic silica beads. The sample is incubated for 10 minutes to allow larger DNA species to bind to the beads. The sample is then placed on a magnetic rack to and the supernatant containing smaller DNA species is transferred to a new tube, leaving behind the magnetic silica beads bound to larger DNA species. In the new tube, additional magnetic silica beads are added and 3 volumes of 100% isopropanol is added. The mixture was incubated at room temperature for 10 minutes, and the supernatant was removed. The DNA was eluted from the silica beads using a 10 mM Tris-HCl + 0.1 mM EDTA buffer. The resulting DNA is a size-selected cfDNA that is 20-60 bp [00127-00128]. Welker teaches that the magnetic silica beads may be Dynabeads MyOne Silane beads [0042]. Welker additionally teaches that the beads can be washed to remove contaminants after removing the beads by subjecting the beads to a magnetic field. The beads can be washed using an alcoholic solution [0067]. Alcoholic solutions in Welker include solutions comprising ethanol [0037]. Welker teaches that DNA can be eluted with an elution buffer adjusted to a pH of between 7.0 to 9.0, such as pH 8.0 [0068]. The methods of Welker may produce an eluate which is enriched with cfDNA fragments of about, among others, 300 base pairs in length (claim 4). Welker teaches that compositions for enriching cfDNA fragments from a biological fluid sample may be provided as kits [00102]. The teachings of Welker differ from that of the instantly claimed invention in that Welker does not expressly teach a washing step after forming a binding mixture or exemplify isolation of cell free DNA from a sample comprising blood plasma. It would have been prima facie obvious for one of ordinary skill in the art to apply the known methods to enriching cfDNA in a biological fluid as taught by Welker to the analysis of DNA in a blood plasma sample to achieve the predictable result of enriched cfDNA from a blood plasma sample. One of ordinary skill in the art would have a reasonable expectation of success because Welker teaches that blood plasma is suitable for use as the biological fluid sample in the discloses method. In addition, one of ordinary skill in the art would have been motivated to wash the magnetic microbeads in the method of Welker with a wash buffer comprising ethanol because Welker teaches that washing the beads using an alcoholic solution, which includes solutions comprising ethanol, removes contaminants from the beads. One of ordinary skill in the art would have a reasonable expectation of success because Welker teaches that a washing step may be included in embodiments of the disclosed method. Welker does not expressly teach that the isopropanol is at around 15-25% v/v in the binding mixture. However, Welker does teach that the addition of alcohol favors the binding of the cfDNA to silica particles, with larger cfDNA fragments binding first followed by binding of smaller cfDNA fragments [0023]. Furthermore, Welker teaches solutions of an alcohol concentration of 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21 %, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, or 10% v/v alcohol. Thus Welker teaches that the alcohol concentration is a result effective variable such that one of ordinary skill in the art would have been motivated to optimize the concentration of alcohol in the binding mixture in order to optimize the size of the bound DNA and thereby optimize the size of cfDNA that is enriched. Regarding instant claims 7, 16, and 23 Welker does not expressly disclose a concentration of a blood plasma sample at around 25-40% v/v in the binding mixture (instant claims 7 and 16) or where 0.5-4 mL of blood plasma is used (instant claim 23). However, Welker teaches that with the lower volume of sample, lower volumes of reagents can be used during the enrichment of cfDNA methods described herein, thus making the downstream isolation procedures more manageable and reducing the amount of required reagents and hence expense [0021]. Welker further teaches that large sample volumes, such as a large volume of blood, are often impractical and put the patient at risk [006]. Thus, one of ordinary skill in the art would have been motivated to optimize the amount of blood plasma used in the method of Welker because Welker teaches that reducing the volume of sample used makes isolation procedures more manageable and less expensive, and safer to patients. Regarding instant claim 19, Welker teaches that the elution buffer is 10 mM Tris-HCl + 0.1 mM EDTA buffer [00128] and that the pH of the elution buffer can be adjusted to a pH 8.0 [0068 and 0092]. The instant specification does not provide a definition for “around” for the limitation of EDTA at around 0.5 mM found in claim 19. The 0.1 mM EDTA buffer of Welker is interpreted as comprising EDTA at around 0.5 mM and thus meets the limitation of the instant claim. Regarding instant claim 21, Welker discloses a method in which a detergent, a chaotropic agent, microbeads and isopropanol are added together and then a sample is added. Instant claim 21 is directed to a method in which a detergent, a chaotropic agent, microbeads, and a sample are added together and then 2-propanol is added. MPEP 2144.04(IV)(C) states that selection of any order of performing process steps is prima facie obvious in the absence of new or unexpected results. Furthermore, selection of any order of mixing ingredients is prima facie obvious. The instant specification was reviewed for evidence of unexpected results. However, the instant specification does not provide data comparing the order of addition of the sample, detergent, chaotropic agent, microbeads, and isopropanol are added in the instantly claimed method. Thus the instant specification does not demonstrate unanticipated results and the method of Welker renders obvious instant claim 21. Regarding instant claim 24, Welker discloses methods and compositions for enriching cfDNA of different size ranges from a biological fluid sample [002]. Welker teaches a method for enriching cfDNA fragments of about 300 base pairs in length (claim 4), and that the methods can also be used to obtain cfDNA fragments having a length of less than about 100 base pairs, such as about 10 base pairs and 80 base pairs [008 and 0027]. As discussed above, Welker additionally teaches one of ordinary skill in the art how to optimize the length of the cfDNA particles that are enriched by optimizing the alcohol concentration (see for example [0023]). Welker additionally teaches that the size of cfDNA fragments correlates to the origin of the cfDNA fragment. For example, large cfDNA fragments originate from the urinary tract while small cfDNA fragments in the urinary tract arise from both the blood and urinary tract system [00116]; cfDNA fragments of 150 bp are typical in size of DNA that is protected by a single octameric nucleosome core [0075]. Thus it would have been prima facie obvious to optimize the cfDNA fragment size distribution obtained in the methods of Welker because it is prima facie obvious to apply a known technique to a known method ready for improvement to yield predictable results, and Welker teaches methods for obtaining cfDNA fragments of different size ranges and teaches that the size of cfDNA fragments to be obtained depends on the desired DNA fragments to be enriched. Claims 3 and 14-15 are rejected under 35 U.S.C. 103 as being unpatentable over Welker et al. (WO 2018/140452; IDS 07/18/2022) as applied to claims 1 and 13 above, in view of Toro et al. (Clinical Biochemistry, 2015; PTO-892 08/05/2025). The teachings of Welker are discussed in detail above. The teachings of Welker differ from that of the instantly claimed invention in that Welker does not teach that the blood plasma is obtained from whole blood collected in cell-free DNA stabilizing tube (instant claims 3 and 14-15). Toro teaches that circulating plasma DNA is being increasingly used for biomedical and clinical research as a substrate for genetic testing. However, cell lysis can occur hours after venipuncture when using standard tubes for blood collection, leading to an increase in contaminating cellular DNA that may hinder analysis of circulating plasma DNA (abstract). Toro compares the efficacy of two cell stabilizing reagents, the cell-free DNA BCT tube and the PAXgene tube, in their ability to prevent lysis and cellular release of genomic DNA of blood samples from cancer patients (abstract). Toro teaches that cell-free DNA BCT tubes have been extensively tested and shown to stabilize cell membranes in whole blood and minimize cell lysis and subsequent release of cellular DNA into plasma and have previously been tested for use in analyzing circulating fetal DNA in maternal blood (paragraph bridging pages 993-994). Toro concludes that cell-free DNA BCT tubes are valuable for plasma DNA analysis of DNA (page 998, paragraph 2). One of ordinary skill in the art would have been motivated to collect the blood sample for analysis by the method of Welker using the cell-free DNA BCT tubes of Toro because Toro teaches that the tubes minimize cell lysis and subsequent release of cellular DNA into plasma that would otherwise hinder analysis of circulating plasma DNA. One of ordinary skill in the art would have a reasonable expectation of success in using the cell-free DNA BCT tubes of Toro to collect samples for use in the method of Welker because Welker teaches that the sample may be blood plasma, and that the sample can be collected by any conventional means. Regarding instant claim 15, the claim recites the method of claim 14 with an additional optional step. The claim encompasses methods that do not expressly include the optional step, and so is met by art meeting the limitations of claim 14. Claim 8-9 and 17-18 are rejected under 35 U.S.C. 103 as being unpatentable over Welker et al. (WO 2018/140452; IDS 07/18/2022) as applied to claims 1, 4, and 13 above, in view of Stray et al. (US 2018/0237841 A1; IDS 07/18/2022). The teachings of Welker are discussed in detail above. Welker further discloses a method for enriching cell-free DNA comprising the step eluting cfDNA fragments from a plurality of DNA-binding particles (claim 1) which are silica magnetic bead particles (claim 2). Welker teaches that the term "elution" or "eluting" refers generally to the process of extracting one material from another by washing with a solvent [0044]. Welker teaches that the elution obtained from the method may be additionally enriched with cfDNA fragments having various lengths, including a length of about 300 base pairs [0073]. Welker also teaches that any number of elution procedures can be used to elute the bound DNA [0068]. Welker teaches an elution buffer that is a 10 mM Tris-HCl + 1 mM EDTA buffer and that the pH of the elution buffer can be adjusted to a pH 8.0 [0068 and 0092]. The teachings of Welker differ from that of the instantly claimed invention in that Welker does not teach a single embodiment in which Triton X-100 is included at around 20-30% (instant claim 8) and guanidinium thiocyanate is included at around 1.5-2.5 M (instant claim 9). Welker also does not expressly disclose washing the beads with a buffer that comprises guanidinium thiocyanate at around 2.0 M and Triton X-100 at about 22% w/v (instant claim 17) or a polysorbate-type non-ionic surfactant (instant claim 18). Stray discloses methods for isolating nucleic acids from a biological sample comprising binding the DNA to a matrix (abstract). The DNA in particular is cfDNA and the matrix may be silica [0030]. Stray teaches that increasing the amount of the detergent Triton (Triton X100) in solution preferentially increased the recovery of small DNA fragments ([0011-0012] and Figures 5-6). Stray teaches that detergents include Triton X100 and TWEEN-20, among others [0042]. Stray further teaches that recovery of short dsDNA increased as the concentration of the chaotropic agent guanidine chloride was increased ([0009-0010] and Figures 3-4). Stray teaches that chaotropic agents include guanidine chloride and guanidine isothiocyanate, among others [0039]. One of ordinary skill in the art would have been motivated include a chaotropic agent such as guanidine isothiocyanate or a detergent such as Triton X100 or TWEEN-20 and to optimize the amounts of these compounds in the elution buffer in the method of Welker because Stray teaches that these compounds can be used to control the size of DNA fragments recovered from a silica matrix in a method for isolating cfDNA. One of ordinary skill in the art would have been similarly motivated to optimize the amount of Triton and chaotropic agent in the binding mixture of Welker in order to control the size of DNA fragments recovered from a silica matrix in a method for isolating cfDNA. One of ordinary skill in the art would have had a reasonable expectation of success because Welker teaches that any number of elution procedures can be used to elute the bound DNA, and that the elution obtained from the method may be additionally enriched with cfDNA fragments having various lengths. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Welker et al. (WO 2018/140452; IDS 07/18/2022) as applied to claims 1 and 11 above, in view of Life Technologies (Dynabeads MyOne Silane Catalog nos. 37002D, 37005D, 2012; PTO-892 08/05/2025). Welker teaches as above. The teachings of Welker differ from that of the instantly claimed invention in that Welker does not teach that the magnetic microbeads are formulated in an aqueous suspension at 20-200 mg/mL. Life Technologies teaches that Dynabeads MyOne Silane provide an excellent tool for highly predictable and consistent isolation of nucleic acids from biological samples (page 1, paragraph 5). The beads are supplied at a concentration of 40 mg/mL in water containing 0.02% sodium azide as a preservative (page 1, paragraph 12). Alternative particles from other suppliers often have a random size range distribution, surface area, and binding capacity. This could compromise the reproducibility of results (page 1, paragraph 4). One of ordinary skill in the art would have been motivated to select Dynabeads MyOne Silane formulated in a 40 mg/mL aqueous suspension as the magnetic microbeads in the method of Welker because Life Technologies teaches that Dynabeads MyOne Silane provide highly predictable and consistent isolation of nucleic acids from biological samples and that alternative particles from other suppliers often have a random size range distribution, surface area, and binding capacity that could compromise the reproducibility of results. One of ordinary skill in the art would have had a reasonable expectation of success because Welker teaches that the magnetic silica beads may be Dynabeads MyOne Silane beads. Response to Arguments Applicant's arguments filed 04/24/2026 have been fully considered but they are not persuasive. Applicant argues that the reference does not exemplify blood plasma and only exemplifies urine (Remarks, page 8, paragraph 5), and that thus one of ordinary skill in the art would not have a reasonable expectation of success in applying the methods of Welker to blood plasma (Remarks, page 9, paragraph 1). This is not persuasive. MPEP 2123(I) states that "The use of patents as references is not limited to what the patentees describe as their own inventions or to the problems with which they are concerned. They are part of the literature of the art, relevant for all they contain...A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill in the art. MPEP2123(II) states that "Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments." The teachings of Welker as a whole suggest methods of cfDNA enrichment that are suitable for use on a variety of biological fluid samples, including blood plasma samples. Although Welker does teach examples including urine as the biological samples and including urine processing steps, Welker does not teach that the urine processing steps are required in the discloses method. As discussed in the above grounds of rejection, Welker teaches collection of a blood sample and that the biological fluid sample in the methods of enriching DNA may be blood plasma or serum, including extracts from a biological sample including a blood sample. Thus the teachings of the prior art as a whole render prima facie obvious the instantly claimed invention wherein the sample comprises blood plasma. Applicant further argues that a person of ordinary skill in the art would not have expected the relative lesser concentration of 2-propanol recited by the Applicant's claims to isolate effectively from blood plasma a sample in which "the majority of the eluted DNA is < 400 bp" (Remarks, page 9, paragraph 2). This is not persuasive. As discussed in the above grounds of rejection, Welker teaches a low alcohol reaction solution for the isolation of small cfDNA fragments, and Welker teaches low alcohol reaction solutions comprising an alcohol concentration of 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21 %, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, or 10% v/v alcohol. Welker further teaches that methods can also be used to obtain cfDNA fragments having a length of less than about 100 base pairs, such as about 10 base pairs and 80 base pairs [008 and 0027]. Thus one of ordinary skill in the art would have expected a lesser concentration of alcohol, such as, among others, 15%, to be used to effectively isolate small cfDNA fragments of less than 100 base pairs. Because Applicant’s arguments are not persuasive, the instant claims are rejected for the reasons of record with modifications made to account for the claim amendments filed 04/24/2026. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarah Grace Hibshman whose telephone number is (703)756-5341. The examiner can normally be reached Monday-Thursday 7:30am-5:30pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached on (571) 270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /S.G.H./Examiner, Art Unit 1693 /SCARLETT Y GOON/Supervisory Patent Examiner Art Unit 1693
Read full office action

Prosecution Timeline

Jul 18, 2022
Application Filed
Aug 05, 2025
Non-Final Rejection mailed — §103, §112
Nov 05, 2025
Response Filed
Feb 25, 2026
Final Rejection mailed — §103, §112
Apr 24, 2026
Response after Non-Final Action
May 01, 2026
Request for Continued Examination
May 04, 2026
Response after Non-Final Action
Sep 01, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12709768
HIGH-PURITY STEVIOL GLYCOSIDES
6y 9m to grant Granted Aug 18, 2026
Patent 12673101
VARICELLA ZOSTER
4y 2m to grant Granted Jul 07, 2026
Patent 12668607
HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
4y 5m to grant Granted Jun 30, 2026
Patent 12653836
Ketogenic Diet and Ketone Supplementation for Cancer Therapy
3y 5m to grant Granted Jun 16, 2026
Patent 12551498
TREATMENT OF P53-DEFICIENT CANCERS
4y 0m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
40%
Grant Probability
85%
With Interview (+44.8%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month